Abstract: A medical diagnostic apparatus includes a receiver circuit that receives three-dimensional data of a subject's eye, and a processor configured to separate portions of the three-dimensional data into separate segments, perform processing differently on each of the separate segments, and combine the separately processed segments to produce a segmented three-dimensional data set. The processor is further configured to generate at least one diagnostic metric from the segmented three-dimensional data set, and the processor is further configured to evaluate a pathological condition based on the at least one diagnostic metric. Related methods and computer readable media are also disclosed.

Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: A method for waking up a smart device includes receiving sound information; determining whether the sound information includes a multi-frequency tone; and when the sound information includes the multi-frequency tone, waking up a preset function of the smart device based on the multi-frequency tone. A device for waking up a smart device as well as a smart device incorporating the device includes processing elements for performing the method. A non-transitory computer-readable storage medium stores computer instructions to cause processing elements to perform the method for waking up a smart device.

Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract: The present application provides methods of treating PI3K? related disorders using compounds of Formula I: or pharmaceutically acceptable salts thereof.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.

Abstract: Optical coherence tomography (OCT) angiography (OCTA) data is generated by one or more machine learning systems to which OCT data is input. The OCTA data is capable of visualization in three dimensions (3D) and can be generated from a single OCT scan. Further, motion artifact can be removed or attenuated in the OCTA data by performing the OCT scans according to special scan patterns and/or capturing redundant data, and by the one or more machine learning systems.

Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: Disclosed are compounds of Formula (I), methods of using the compounds for inhibiting ALK2 activity and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders associated with ALK2 activity such as cancer.

Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.

Abstract: The present disclosure provides bifunctional compounds comprising a target protein binding moiety and a E3 ubiquitin ligase binding moiety, and associated methods of use.

Abstract: The disclosure is directed to compounds of Formula I Pharmaceutical compositions comprising compounds of Formula I, as well as methods of their use and preparation, are also described.

Abstract: The present application provides tricyclic urea compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.

Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: Optical coherence tomography (OCT) angiography (OCTA) data is generated by one or more machine learning systems to which OCT data is input. The OCTA data is capable of visualization in three dimensions (3D) and can be generated from a single OCT scan. Further, motion artifact can be removed or attenuated in the OCTA data by performing the OCT scans according to special scan patterns and/or capturing redundant data, and by the one or more machine learning systems.

Abstract: This application relates to compounds of Formula I: or pharmaceutically acceptable salts thereof, which are inhibitors of TAM kinases which are useful for the treatment of disorders such as cancer.

Abstract: The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: The present invention provides tricyclic fused thiophene derivatives, as well as their compositions and methods of use, that modulate the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.

Abstract: An ultrasonic data transmission method, apparatus and system, a terminal device and a medium are provided. The method is applied to a transmitting terminal which includes at least two ultrasonic signal transmitting arrays. The method includes: a single-frequency ultrasonic coding signal of to-be-transmitted information corresponding to each ultrasonic signal transmitting array is respectively determined, ultrasonic codes of to-be-transmitted information corresponding to different ultrasonic signal transmitting arrays being different; and corresponding at least two single-frequency ultrasonic code signals are transmitted through the at least two ultrasonic signal transmitting arrays to a receiving terminal in a focusing mode, frequency bands of transmitting frequencies of different ultrasonic signal transmitting arrays being different.

Abstract: The present invention provides heterocyclylamine derivatives of Formula I: wherein the variables are defined herein, that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.